Statement attributable to:

Susan R. Bailey, M.D.

American Medical Association President

“The recommendation approved today by the Advisory Committee on Immunization Practices (ACIP) for the use of the Janssen Pharmaceutical Companies of Johnson & Johnson COVID-19 vaccine in adults age 18 and older in the U.S. population is another major step toward vaccinating millions of people across the country. The new vaccine – a single-shot variety with logistical advantages over previously authorized vaccines – moves us still closer to reducing the incidence of death and severe illness from COVID-19 by offering a third safe, effective vaccine that can be used across the country. Each of the authorized COVID-19 vaccines were studied at different times, in different locations, and under different conditions, making direct comparisons difficult, but importantly they have all undergone rigorous, transparent development, testing and authorization, and all three vaccines are highly effective at preventing hospitalization and death from COVID-19. When it’s your turn to get vaccinated, we urge you to take the first vaccine available to you. Even after you’ve been vaccinated, we urge you to continue wearing your mask, maintaining physical distancing and washing your hands to prevent the spread of COVID-19 to those who haven’t yet been vaccinated.

“The AMA applauds the FDA and its Vaccines and Related Biological Products Advisory Committee as well as the CDC and its Advisory Committee on Immunization Practices for continued transparency in the process for both authorization and recommended use of COVID-19 vaccines. We look forward to the CDC Director’s review and approval of ACIP’s recommendations on use of this vaccine in the U.S. population to control COVID-19. The AMA will also work to ensure physicians are aware of ACIP recommendations for use of all authorized COVID-19 vaccines, as well as their recommendations for prioritizing allocation of the vaccine.”